I closed my positions on Tuesday. I'm 60% plus YTD and now I'm shorting BIOTECHS as correction continues into Sept. BIOTECH froth is outrageously idiotic and will end in Sept I'm Shorting REGN JAZZ ALXN may add ILMN
Now that Amgen has posted a price slightly less than Regeneron regular dosage Regeneron can price its lower dosage substantially less than Amgen and get market share..
In my estimation, Regeneron has a few years left before they need to worry about Ocata's therapy.
Right now, Eylea constitutes the majority of the revenue. That could change pretty rapidly though assuming RPE commercialization for dry AMD. I realize Regeneron has a lot in the pipeline, but wiping out Eylea sales would certainly put pressure on future earnings estimates for the company. If Ocata's dry AMD trials are in any way expedited, then in my opinion, Eylea sales estimates will start falling in dramatic fashion. Folks will say REGN is treating a different eye disease, but they aren't aware of the precursor condition that Ocata has the potential to treat.
Robust data is king, and by this time next year we will see some interim results for the blinded phase two dry amd trial.
OCAT also has had a major move up right in the face of a 1000 point decline in the DOW Jones Industrials. Meanwhile REGN falls with the popping of the Fed created bubble.
OCAT's RPE cell technology can put Eylea(tm) out of business. OCAT will soon be starting a pivotal trial in Stargardt's macular degeneration in addition to a controlled trial in dry age-related macular degeneration.
bump! see ya at $300 soon. you won't believe your eyes when it happens.
How do people feel this will affect REGN stock price next week? What about the impact of how AMGN prices its drug once approved by FDA? How much do people feel AMGN has to undercut REGN's price in order to be anti-cholesterol drug? Thanks in advance for your thoughts
OCAT just raised cash today in a very creative non-dilutative financing. They are about to start an efficacy trial for dry age-related macular degeneration (AMD) and a pivotal trial for Stargardt's macular degeneration (SMD). The stock was up 12% today. OCAT only has 40 million shares outstanding, and a market cap of only $150 million. Once they confirm the efficacy they saw in the P1 trial, this stock is going to $300 plus. The market, as REGN investors know, for AMD is HUGE!
Time to take some profits off the table here and invest them in OCAT, in my humble opinion. I see OCAT as being the next REGN and then some.